Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose bladder cancer more accurately than current standard methods.
Read full article here.
The UK's national research agency is backing a plan to speed up dementia testing with up to £80 million ($105.48 million) in funding, to improve diagnosis rates and cut waiting times that can exceed a year.
Read full article at Medscape…
Attendees
Sponsors and Exhibitors
Contact us